At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 234 enrolled
Drug / intervention
Linagliptin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIIb, 24-week, Randomised, Placebo-controlled, Double-blinded, Efficacy and Safety Study of Linagliptin (BI 1356) in Black/African American Patients With Type 2 Diabetes With a MTT Sub-study
In Brief
A Phase 3 clinical trial evaluating Linagliptin and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 234 participants across 93 sites.
Detailed Summary
Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2010
First PostedSep 2010
Primary CompletionOct 2011
TodayJul 2026
First PostedSep 3, 2010
Enrollment StartSep 1, 2010
Primary CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 15.8 years ago
Interventions
Linagliptindrug
Active drug 1 tablet PO QD
Placebodrug
1 Tablet PO QD